Add time:08/04/2019         Source:sciencedirect.com

IntroductionBecause osteoporotic patients are prone to fractures, it must be considered whether or not patients undergoing drug therapies should discontinue treatment after sustaining a non-vertebral fracture. This study has tested the effect of novel active vitamin D3 analog, 1α,25-dihydroxy-2β(3-hydroxypropoxy)vitamin D3 (ED-71), on the fracture healing comparing with a powerful anti-resorptive agent, alendronate, using a rat femoral fracture model.

We also recommend Trading Suppliers and Manufacturers of 2-(3-hydroxypropoxy)-1,25-dihydroxyvitamin D3 (cas 104121-92-8). Pls Click Website Link as below: cas 104121-92-8 suppliers